insulin aspart
Brand: NovoLog, Fiasp
ISMP High Alert Prototype Drug
Drug Class: insulin
Drug Family: insulin
Subclass: rapid-acting insulin analogue
Organ Systems: endocrine
Mechanism of Action
Rapid-acting insulin analogue with aspartate substitution at B28 reducing self-association and enabling faster absorption; activates insulin receptor, stimulating glucose uptake, glycogen synthesis, lipogenesis, and protein synthesis while suppressing gluconeogenesis and glycogenolysis.
insulin receptor
Indications
- type 1 diabetes (bolus/mealtime insulin)
- type 2 diabetes (mealtime insulin)
- continuous subcutaneous insulin infusion (insulin pump)
Contraindications
- hypoglycemia
- hypersensitivity to insulin aspart
Adverse Effects
Common
- hypoglycemia (most common)
- injection site reactions
- weight gain
- hypokalemia
Serious
- severe hypoglycemia
- anaphylaxis (rare)
Pharmacokinetics (ADME)
| Absorption | SC: onset 10–20 minutes; IV: immediate onset (100% bioavailability) |
| Distribution | Widely distributed |
| Metabolism | Cleaved by insulin-degrading enzyme in liver, kidney, and peripheral tissues |
| Excretion | Renal |
| Half-life | ~81 minutes (SC) |
| Onset | SC: 10–20 minutes; IV: immediate |
| Peak | 40–50 minutes (SC) |
| Duration | 3–5 hours |
| Protein Binding | minimal |
| Vd | N/A (SC) |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| beta-blockers | mask hypoglycemia symptoms (tachycardia) | moderate |
| alcohol | may potentiate hypoglycemia | moderate |
Nursing Considerations
- Administer 5–10 minutes before a meal (Fiasp can be given at meal start or up to 20 minutes after starting meal); onset must match meal absorption to prevent hypo/hyperglycemia
- IV insulin aspart must be used at 0.05–1 unit/mL concentration in NS; insulin adsorbs to IV tubing — flush before use
- Monitor glucose every 1–2 hours in patients on insulin infusion protocols; adjust infusion rate per protocol
- Rotate injection sites; abdomen has fastest absorption, followed by arms, thighs, and buttocks
Clinical Pearls
- Rapid-acting insulin analogues (aspart, lispro, glulisine) should be administered 5–15 minutes before meals — their rapid onset requires meal-to-injection timing to avoid hypoglycemia from timing mismatch
- Fiasp (faster-acting aspart) contains vitamin B3 and L-arginine to accelerate absorption, achieving onset in 2–4 minutes and peak in 60–90 minutes — useful for post-meal dosing flexibility
Safety Profile
Pregnancy safe
Lactation safe
Renal Adjustment Required
Hepatic Adjustment Required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.